Contents

Part I  Introduction

Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer: Open Questions for Research .............................. 3
1 How can the Study of MRD and CTCs Help Us to Better Understand Breast Cancer Metastasis? ................................. 4
2 Is There any Preferred Technology for CTC Detection and Characterization? ..................................................... 4
3 What is the Role of Other Blood-Based Biomarkers like Circulating Enothelial Cells and Circulating Nucleic Acids? ...... 4
4 Should DTC/CTC Detection and Characterization be Used in Current Clinical Practice? ........................................ 5
5 What are the Challenges in Drug and CTC Co-Development? .................................................................................. 5
6 Future Perspectives .................................................................................................................................................. 5
References ............................................................................................................................................................... 6

Part II  Minimal Residual Disease and Breast Cancer Metastasis

Self-Seeding in Cancer .................................................................................................................................................. 13
1 Introduction ............................................................................................................................................................. 14
2 Self-Seeding Model of Malignant Growth: The Biological Basis for Self-Seeding .............................................. 14
3 Mathematical Foundation of Self-Seeding .............................................................................................................. 15
4 Prevailing Mysteries: Unpredictable Metastatic Pathways ...................................................................................... 16
  4.1 Why do Some Patients Without Axillary Nodal Involvement Still Develop Systemic Metastases? And Why do Some Patients With Axillary Nodal Metastases not Develop Metastases Elsewhere, Even If Those Nodal Metastases are not Removed by Surgery or Irradiated? ...................................................................................... 16
  4.2 Why is it That so Few Patients Present With Gross Metastatic Disease, Even When They May Have Large Untreated Tumors for a Long Time? ...................................................................................... 18
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>26</td>
</tr>
<tr>
<td>2</td>
<td>Theoretical Considerations and Evidence for the Potential Scenarios of Tumor Dormancy</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>2.1 Scenario 1: The Target Organ Microenvironment as a Determinant of DTC Dormancy</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>2.2 Scenario 2: Primary Tumor “Stress Microenvironments” Determine DTC Fate</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>2.3 Scenario 3: Early Dissemination as a Determinant of DTC Dormancy</td>
<td>33</td>
</tr>
<tr>
<td>3</td>
<td>Conclusions and Perspectives</td>
<td>36</td>
</tr>
<tr>
<td>4</td>
<td>References</td>
<td>37</td>
</tr>
</tbody>
</table>

**Part III  Technologies for Circulating Tumor Cell and Disseminated Tumor Cell Detection and Characterization**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>44</td>
</tr>
<tr>
<td>2</td>
<td>CTC Enrichment and Detection Methods</td>
<td>44</td>
</tr>
<tr>
<td>3</td>
<td>Detection of CTCs by Flow Cytometry without Prior Enrichment</td>
<td>46</td>
</tr>
<tr>
<td>4</td>
<td>Immunomagnetic CTC Enrichment</td>
<td>48</td>
</tr>
<tr>
<td>5</td>
<td>Detection of Immunomagnetically Enriched CTCs by Flow Cytometry</td>
<td>50</td>
</tr>
<tr>
<td>6</td>
<td>Detection of Immunomagnetically Enriched CTCs by Microscopy</td>
<td>52</td>
</tr>
<tr>
<td>7</td>
<td>References</td>
<td>54</td>
</tr>
</tbody>
</table>

**Microfluidic Technologies**

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>60</td>
</tr>
<tr>
<td>2</td>
<td>Physical Separation Methods</td>
<td>62</td>
</tr>
<tr>
<td>3</td>
<td>Affinity-Based Separation Methods</td>
<td>64</td>
</tr>
<tr>
<td>4</td>
<td>Conclusions and Future Outlook</td>
<td>65</td>
</tr>
<tr>
<td>5</td>
<td>References</td>
<td>66</td>
</tr>
</tbody>
</table>
4 Conclusions .......................................................... 157
References .............................................................. 158

Circulating Endothelial Cells and Circulating
Endothelial Progenitors ............................................ 163
1 Introduction ........................................................... 164
2 CEC and CEP Phenotypes ........................................ 164
3 CEC Kinetic and Cancer Treatment ............................ 165
4 CEP Role in Cancer Growth and Metastasis Development . 166
5 Conclusions .............................................................. 167
References .............................................................. 168

Part V Disseminated Tumor Cells and Circulating Tumor Cells
in Breast Cancer Clinical Research and Practice

DTCs in Breast Cancer: Clinical Research and Practice ....... 173
References .............................................................. 177

CTCs in Primary Breast Cancer (I) ................................. 179
1 Introduction ........................................................... 180
2 CTC Detection by Immunocytochemistry ..................... 180
3 Prevalence and Prognostic Relevance of CTCs in the Context
   of Neoadjuvant Treatment .................................... 181
4 Prognostic Value of CTCs Before Adjuvant Chemotherapy . 182
5 CTC Evaluation Immediately After Chemotherapy
   and During Recurrence-Free Follow-Up ..................... 183
6 Conclusions and Therapeutic Implications .................... 183
References .............................................................. 184

CTCs in Primary Breast Cancer (II) ................................. 187
1 Introduction ........................................................... 188
2 CTC Detection by RT-PCR for CK19 mRNA .................. 188
3 Prognostic Value Before Adjuvant Chemotherapy .......... 188
4 Prognostic Value After Adjuvant Chemotherapy .......... 189
5 Prognostic Value in Molecular Subtypes ..................... 190
6 Prognostic Value During Hormonotherapy and Follow-Up . 190
7 Conclusions .............................................................. 191
References .............................................................. 192

CTCs in Metastatic Breast Cancer ................................ 193
1 Introduction ........................................................... 194
2 CellSearch® System for CTC Identification in MBC ......... 195
3 Clinical Implication of CTC Molecular Characterization .. 197
References .............................................................. 199
HER2-Positive DTCs/CTCs in Breast Cancer

1 Introduction .................................................. 204
2 Evaluation of the HER2 Status of DTCs/CTCs .......... 205
3 Clinical Impact of HER2-Positive DTCs/CTCs in Primary Breast Cancer .................................. 206
4 Clinical Impact of HER2 Positive DTCs/CTCs in Metastatic Breast Cancer .................................. 208
5 Conclusion and Perspectives ............................... 210
References .......................................................... 210

DTCs/CTCs in Breast Cancer: Five Decades Later

1 Metastatic Breast Cancer ................................... 218
2 Early Stage Breast Cancer .................................. 221
3 Recommendations ............................................ 223
References .......................................................... 223

Part VI Drug and Circulating Tumor Cell Co-development

Challenges in Drug and Biomarker Co-Development .......... 229
1 Introduction .................................................. 230
2 When Should Co-Development Be Considered? .......... 231
3 General Issues to Be Considered in Co-Development .... 231
4 Assay Development in the Context of Co-Development: Planning for Success ................................ 233
5 Regulatory Challenges in Co-Development ............... 235
6 Conclusions .................................................... 236
References .......................................................... 237

Challenges and Opportunities in the Use of CTCs for Companion Diagnostic Development ..................... 241
1 Introduction .................................................. 242
2 On the Relevance of CTCs as a Source of Representative Cancer Tissue for Predictive Dx ..................... 242
3 Technologies for Molecular Characterization of CTCs .... 243
4 HER2 Diagnostics in CTCs .................................. 246
5 Applications of Predictive Biomarker Analyses in CTCs to Treatment of Metastatic and Early Stage Disease . 247
6 The Path Forward ............................................. 248
7 Conclusions .................................................... 249
References .......................................................... 250
Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
Ignatiadis, M.; Sotiriou, C.; Pantel, K. (Eds.)
2012, XIV, 254 p., Hardcover
ISBN: 978-3-642-28159-4